skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Tanezumab (Code C71522)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Tanezumab

Definition: A humanized monoclonal antibody directed against nerve growth factor (NGF), a modulator of nociceptor function, with potential analgesic activity. Tanezumab binds to NGF and prevents NGF binding to its high affinity, membrane-bound, catalytic receptor tropomyosin-related kinase A (TrkA), which is present on sympathetic and sensory neurons; reduced stimulation of TrkA by NGF inhibits the pain-transmission activities of these neurons. NGF, a neurotrophin, is critical to the growth and maintenance of sympathetic and sensory neurons. In addition, NGF may induce mast cells to release inflammatory proteins and may induce the upregulation of substance P and other pain-related peptides in sympathetic and sensory neurons. Upon neurotrophin binding, TrkA phosphorylates itself and members of the MAPK pathway, mediating the multiple neuronal effects of NGF.

Display Name: Tanezumab

Label: Tanezumab

NCI Thesaurus Code: C71522 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2346819  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-NGF Monoclonal Antibody RN624

External Source Codes: 
CAS Registry Number 880266-57-9 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 575320
PDQ Open Trial Search ID 575320 (check for NCI PDQ open clinical trial info)
UMLS CUI C2346819

Other Properties:
     Name Value (qualifiers indented underneath)
code C71522
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-NGF_Monoclonal_Antibody_RN624
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom